This stock suffers from what Wall Street believes is a clueless management team. They are going to EASL with data from interferon based studies which everyone besides Vertex management knows is throwing good money after bad.
If the 770/809 data isn't well beyond expectations, Morgan Stanley's mid-$20's price target will be way too high.
I took no attitude... I have not been the person you have been playing tit for tat with on the mb.
I was merely commenting that your response did not seem to indicate that you may have considered what the previous poster may have stated based on my interpretation... which was simply a different read on the intent behind, "I am not going to tell you what I know."
Moving from stage left to center... I do in fact have a detailed market analysis and a corresponding DCF analysis of each of the indications addressed in Vertex's pipeline, and no, I don't have an interest in changing your opinion, or anyone else's for that matter... so I won't be providing figures other than I am 'holding' profitably at this stage.
All I will do is wish you luck in your endeavors.
The company needs to be bought out and the management team replaced.
That's really the only way we're going to get solid (and accurate) valuation of this company and stock, regardless of how strong the pipeline is and how good the fundamentals are, including the balance sheet.
I'm really hoping for a big pharma to step in and take over this ship.
But why take that attitude? If you have a well thought through, detailed analysis of the Vertex pipeline I'm more than happy to consider it and change my opinion if warranted. To be honest, my main beef with Vertex is the ineffectiveness of management to effectively communicate the business plan and I don't think Jeff Leiden is the man for that job.
But don't speak in generalities and then say I can't tell anyone what I know; that's just weak.
I dont think it was meant for the broad audience to " take seriously" cross... I think it was meant for you to read between the lines ... And what i read is that it was a nice way of saying "I think your valuation is a load of crap and I am not going to waste my time educating you" -
I believe you are a genius along with those on Wall Street.
Who really cares about HepC beyond two-four years from now.
With 4-5 companies with all good oral treatments (BMY, GILD, ABT, VRTX)the price of drugs that can be charged will all compete with one another. Most people with good insurance will already have sought treatment instead of waiting that long.
Please have those companies go to 3rd world countries were most of the hepc patients reside and try to charge 30K per year. Let alone our health care system is going bankrupt.
So for the next 2 years, VRTX will be filling their coffers for bigger long term therapies.
Remember, your still a genius crossroads. Don't let anyone else tell you otherwise. Best. HS, md
Who cares about HCV beyond 2-4 years? Seriously? Want a list? 11b for Pharmasset ring a bell? INHX?
Filling the coffers at $1.5b in revenue premiere is going to start to feel a little light when it dries up without these proven "bigger long-term therapies" that apparently only you have detailed knowledge of.